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Abstract
Objective—To investigate how acetylcholinesterase inhibitor (ChEI) treatment impacts brain
function in Parkinson’s disease (PD).
Methods—Twelve patients with PD and either dementia or mild cognitive impairment
underwent task-free functional magnetic resonance imaging before and after three months of ChEI
treatment and were compared to 15 age and sex matched neurologically healthy controls. Regional
spontaneous brain activity was measured using the fractional amplitude of low frequency
fluctuations.
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Results—At baseline, patients showed reduced spontaneous brain activity in regions important
for motor control (e.g., caudate, supplementary motor area, precentral gyrus, thalamus), attention
and executive functions (e.g., lateral prefrontal cortex), and episodic memory (e.g., precuneus,
angular gyrus, hippocampus). After treatment, the patients showed a similar but less extensive
pattern of reduced spontaneous brain activity relative to controls. Spontaneous brain activity
deficits in the left premotor cortex, inferior frontal gyrus, and supplementary motor area were
restored such that the activity was increased post-treatment compared to baseline and was no
longer different from controls. Treatment-related increases in left premotor and inferior frontal
cortex spontaneous brain activity correlated with parallel reaction time improvement on a test of
controlled attention.
Conclusions—PD patients with cognitive impairment show numerous regions of decreased
spontaneous brain function compared to controls, and rivastigmine is associated with
performance-related normalization in left frontal cortex function.
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acetylcholine (D02.092.211.111); magnetic resonance imaging functional (E01.370.350.825.500);
attention (F02.830.104.214); Acetylcholinesterase Inhibitors (D27.505.519.389.275) executive
control (F02.463.217)
Introduction
Cholinergic deficits are pronounced in Parkinson’s disease (PD) and are a primary substrate
of debilitating cognitive symptoms including attention and executive dysfunction (1–4).
Acetylcholinesterase inhibitors (ChEIs), including rivastigmine and donepezil, have been
associated with symptomatic improvements (5, 6). In a randomized controlled study of
rivastigmine in 487 patients with PDD, significant benefits over placebo were seen on four
measures of attention (7). Treatment was associated with enhanced attention compared to
baseline, suggesting that rivastigmine was not simply preventing further deterioration but
rather improved brain activity relevant for attention.
To elucidate the neural systems that underlie the effects of ChEIs on attention in PD, we
investigated spontaneous brain activity in cognitively impaired PD patients compared to
controls at baseline and after 3 months of rivastigmine treatment. To measure brain activity,
we selected fractional amplitude of low frequency fluctuations (fALFF), a metric derived
from task-free functional magnetic resonance imaging (fMRI) that represents the power of
regional spontaneous and intrinsic brain activity at the local, voxel-wise level while the
subject is at rest (8, 9). More specifically, the amplitude of low-frequency fluctuations
(ALFF) is the total power in the low-frequency range, and fALFF is calculated by dividing
ALFF by the total power across all measurable frequencies. Whereas ALFF values increase
near blood vessels and CSF, likely due to pulsations in those areas, fALFF is less susceptible
to artifactual signals (8, 10). Inter-individual differences in fALFF at rest were recently
shown to predict performance on an Eriksen flanker test of attention, and in addition, to
predict the magnitude of BOLD activation evoked during flanker task performance during a
separate fMRI scan (11). This study and others (9, 12) validate fALFF as a measure of
intrinsic brain activity relevant to evoked brain activity and behavior.
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We hypothesized that prior to rivastigmine treatment, spontaneous brain activity would be
lower in PD compared to controls, with the most notable decreases in motor areas including
the striatum and motor cortex that are affected by PD, and in regions affected in the earlier
stages of Lewy body deposition including the brainstem, thalamus, striatum, and mesocortex
(13). The nucleus basalis – neocortical cholinergic system contributes greatly to attentional
function (14) and ChEIs improve attention and executive functions in PDD (1, 7).
Accordingly, we hypothesized that rivastigmine would restore brain activity to normal levels
in regions important for the control of attention including the frontal lobes. Further, we
hypothesized that this restoration of brain activity would correlate with improvements in
controlled attention. Cholinergic activity in prefrontal cortex facilitates cue detection in rats
and is thought to bias attention from a default state to a state fostering vigilance toward
sensory information (15–17). Guided by these studies, we selected a test of controlled
attention that requires sustained vigilance and rapid cue detection.
Methods
Subjects
Patients were recruited from University of California, San Francisco (UCSF) movement
disorders neurologists, regional PD support group meetings and advertisements in PD
newsletters. Exclusion criteria included sinus bradycardia; abnormal Vitamin B12,
methylmalonic, RPR or TSH levels (unless on treatment for thyroid condition); prior brain
surgery; history of significant drug or alcohol abuse; history of encephalitis, multiple
sclerosis, CNS infection, epilepsy, or primary CNS disease besides PD; prior exposure to
neuroleptic agents; and use of ChEI within 6 weeks of baseline evaluation of study.
Neurologically healthy controls matched on age, gender, and education were recruited from
the UCSF Memory and Aging Center project on healthy aging (18) (Table 1). All subjects or
their responsible family members gave written informed consent prior to participation in the
study, which was approved by the UCSF committee on human research.
Diagnoses of patients and controls were based upon neurological history and examination,
an interview with a family member, and a brief neuropsychological assessment previously
described (19). Three patients, from an original sample of 15, dropped out due medication
side effects: lightheadedness or dizziness in 2 subjects and gastrointestinal distress in 1
subject. In the sample that completed the study, 6 patients were diagnosed as PDD (20) and
6 patients were diagnosed as PD-MCI (21). The MCI subtypes were MCI-executive (N=1),
MCI-executive, memory (N=1), MCI-executive, visuospatial (N=1), MCI-executive,
memory, attention/working memory (N=2), and MCI-executive, memory, attention/working
memory, visuospatial (N=1).
Study Medication
The Exelon patch (rivastigmine, Novartis International AG, Basel, Switzerland) was
administered at a dosage of 4.6 mg/24 hours from baseline to week 4 and at 9.5 mg/24 hours
from week 4 to 12. All patients were taking optimal doses of dopamine replacement therapy
prescribed by their neurologist. No subjects initiated new medications or new dosages of
current medications during the study. Neuroimaging and cognitive testing occurred at the
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same time of day at baseline and post-treatment whilst “on” to minimize the effects of
dopamine fluctuations on brain activity. We did not withhold dopaminergic medications
during image acquisition because head motion can compromise image quality (22).
Clinical Assessments
The Unified Parkinson’s Disease Rating Motor Scale (UPDRS) was administered by a
movement disorders trained neurologist at baseline after 12 hours of PD medication
withholding. The cognitive assessment was performed at least 45 minutes after subjects took
their PD medications when the patients reported feeling in the “on” state. Two cognitive
measures were administered at baseline and post-treatment: the Montreal Cognitive
Assessment Scale (MoCA) to measure global cognition, and a longer version of the NIH
EXAMINER Continuous Performance Test (CPT) to measure controlled attention
(examiner.ucsf.edu). On the CPT, subjects press the spacebar quickly when they see a target
image (a white star; 150 trials), and withhold response when they see a non-target image (5
randomly sampled white shapes; 150 trials). The inter-stimulus interval is randomly sampled
from 1.5s, 2.5s, or 4s. Performance is measured by the median reaction time (milliseconds)
on accurate target trials. Accuracy was high with only one poor performance at baseline
(67% accurate) and all other performances exceeding 88%. Due to minimal variance in
accuracy, we did not analyze accuracy further. Excluding the subject with poor accuracy at
baseline did not alter any of the CPT results and we retained his data. Data were missing for
two of the patients on the CPT post-treatment due to a computer error.
Image Acquisition
Magnetic resonance images of all subjects were acquired at the UCSF Neuroscience
Imaging Center on a 3 Tesla Siemens Tim Trio scanner equipped with a 12-channel receiver
head coil. A volumetric magnetization prepared rapid gradient echo (MP-RAGE) sequence
was used to obtain T1-weighted images of the entire brain (TR/TE/TI = 2300/3/900 ms, flip
angle of 9 degrees, a bandwidth of 240 Hz/pixel, sagittal orientation with a FOV = 256 ×
240 mm, 1×1×1 mm3 resolution, and 160 slices). “Resting state” or task-free fMRI scans
were obtained using 36 axial slices (3 mm thick) parallel to the plane connecting the anterior
and posterior commissures and covering the whole brain using a T2*-weighted gradient
echo–echo planar sequence (TR/TE = 2000/27 ms, flip angle 80°; FOV = 230 × 230 mm;
matrix size: 92 × 92; 3 mm slices with 2.5 × 2.5 × 3 mm resolution). All subjects underwent
8 minutes of scanning (240 images) after being instructed only to remain awake with their
eyes closed.
Image Preprocessing
Image processing was performed with SPM8. After discarding the first eight frames to allow
for magnetic field stabilization, functional images were realigned, slice-time corrected, co-
registered to their T1-weighted images, normalized to standard space and smoothed with a
4mm full-width at half-maximum Gaussian kernel (normalization and smoothing were
carried out in one step using DARTEL toolbox). The images were resampled at a voxel size
of 2 mm3.
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Head Motion Assessment
Head movements were assessed using the rigid body parameters provided by the SPM8
realign algorithm. All subjects had minimal movements (maximum translation < 2 mm and
maximum rotation < 2 degrees). To assess for group differences and differences between the
two time points in head motion, mean root-mean-square (RMS) values of volume-to-volume
changes were computed for translation and mean Euler angles for rotation, as these
summary metrics have been shown to correlate with network connectivity strength (22). At
neither time point did the PD patients differ in translational or rotational movement
compared to controls, nor did the two time points within the PD group differ from each
other, all ps > .05 (Table 1).
fALFF Preprocessing and Group Analyses
Amplitude of low frequency analysis was performed using the REST toolbox, following
previous methods (8). After preprocessing, each voxel’s BOLD signal time series was
detrended and transformed to the frequency domain to obtain the power spectrum. The
power of a given frequency is measured as the square of the amplitude at each frequency of
the power spectrum. We focused on the low frequency range from 0.01–0.08 Hz because
coherent fluctuations in this range are dominant in gray matter and are thought to reflect
neural activity, whereas coherent fluctuations above this range are more influenced by
cardiovascular or respiratory fluctuations (10). To further reduce the impact of physiological
artifact, fALFF was computed by dividing the sum of the square roots across the 0.01–0.08
Hz range by that across the entire frequency range (0–0.25 Hz). fALFF methods have been
detailed and validated in previous publications (9–12, 23–25).
fALFF group comparisons were evaluated using t-tests and statistically thresholded using
the joint probability distribution method to correct for multiple comparisons at the whole
brain level (26), p < 0.01 for voxel height and p < 0.05 for cluster extent. Voxel-wise fALFF
in gray matter was compared between controls and patients, separately for each time point.
To determine if there were treatment-associated changes in brain activity, we compared the
patients at baseline to post-treatment. Because we were interested in the effects of ChEIs on
abnormal activity, only regions with reduced fALFF compared to controls at either time
point were included.
Two clusters differed in fALFF between baseline and post-treatment, and we computed
mean fALFF of those voxels. To determine whether the changes resulted in a normalization
of brain activity, we compared the mean fALFF values of the patients at each time point to
controls using t-tests. In addition, to determine the behavioral relevance of these changes,
mean fALFF change scores were calculated for these clusters in the patients (post-treatment
minus baseline) and were entered into correlation analyses with changes in the cognitive
variables (post-treatment minus baseline).
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Results
Performance on the cognitive measures
On the MoCA, the patients did not differ between baseline, 23.0 +/− 4.8, and post-treatment,
24.3 +/− 4.7, assessments, p = 0.16. On the CPT, the patients’ median reaction time did not
differ between baseline, 579 +/− 108, and post-treatment, 571 +/− 108, assessments, p =
0.44.
Spontaneous brain activity differences between patients and controls
At both baseline and post-treatment, the patients exhibited reduced fALFF compared to
controls in several lateral and medial frontal regions including motor areas (e.g., bilateral
supplementary motor area) and regions important for executive control (bilateral superior,
middle, and inferior frontal gyri). The left hippocampus, the bilateral precuneus and the
bilateral angular gyrus, which are regions often targeted by Alzheimer’s disease, also
showed reduced fALFF at both timepoints. Regarding subcortical structures, the bilateral
caudate and the left thalamus showed decreased fALFF at baseline, and the right caudate
and the left thalamus showed decreased fALFF at post-treatment, compared to controls. We
found prominent medial occipital reductions, particularly at baseline. Overall, a similar
group-level pattern of decreased fALFF was found at both time points compared to controls,
but the deficits were more extensive at baseline (4,614 voxels) than post-treatment (2,339
voxels) (Supplementary Tables; Figure 1). The patients did not show increased fALFF in
any regions compared to controls at either time point.
Normalization of spontaneous brain activity associated with treatment
To determine whether rivastigmine had any restorative effects on brain function, we created
a mask of regions where the patients showed abnormally low fALFF at either timepoint (i.e.,
the regions depicted in Figure 1). Next, we compared regional fALFF voxel-wise between
baseline and post-treatment within the mask. Results indicated that after treatment the
patients showed increased fALFF in two clusters: (1) the left precentral gyrus/inferior
frontal gyrus pars opercularis and (2) the left supplementary motor area (Table 2). No
regions showed higher fALFF at baseline compared to post-treatment. To determine whether
these fALFF changes reflected a restoration of brain function to normal levels, mean fALFF
was extracted from all voxels within each cluster for patients at each time point and for the
controls. As expected, the patients showed reduced fALFF compared to controls in both the
left precentral/inferior frontal gyri cluster, d = −1.56, and the left supplementary motor area
cluster, d = −1.50, both ps < 0.001. These levels were restored post-treatment such that the
patients no longer differed significantly from controls in the left precentral/inferior frontal
gyri, d = −0.25, p = 0.52, or the left supplementary motor area, d = −0.69, p = 0.09. Because
the patient-only within-subjects comparison was used to identify the two clusters, the
observed “normalization” was not the result of statistical dependency (27).
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Correlations between post-treatment increases in fALFF and changes in cognitive
performance
To determine whether the treatment-associated increases in fALFF were behaviorally-
relevant, we correlated the increases in fALFF with changes in global cognition (MoCA)
and controlled attention (CPT). Increases in fALFF in the left premotor/inferior frontal gyri
cluster correlated with decreases in reaction time on the CPT, r = −0.82, p < 0.01, but not
change on the MoCA, r = 0.18, p = 0.58. In the left supplementary motor area cluster,
increased fALFF did not correlate significantly with changes on the CPT, r = −0.35, p =
0.36, or the MoCA, r = 0.26, p = 0.41 (Figure 2).
Discussion
Rivastigmine is an FDA-approved medication for the symptomatic treatment of PDD with
beneficial effects on cognitive and psychiatric symptoms, including attention and executive
functions (5). To investigate the neural systems influenced by the treatment effect, we
examined spontaneous brain activity before and after 3 months of rivastigmine treatment in
a cognitively impaired PD sample versus controls using fALFF, a new measure of
spontaneous brain activity intensity derived from task-free fMRI (8). At baseline, the PD
patients showed numerous regions of decreased spontaneous brain activity and no regions of
increased spontaneous brain activity compared to controls. After 3 months of treatment, the
pattern of decreased spontaneous brain activity was topographically similar but less
extensive. Rivastigmine treatment was associated with restoration of spontaneous brain
activity in the left premotor gyrus, the left inferior frontal gyrus pars opercularis, and the left
supplementary motor area. The degree of treatment-associated increases in left premotor and
inferior frontal gyri brain activity was associated with improvements in controlled attention.
The results suggest that rivastigmine may support cognitive function in cognitively impaired
PD patients by enhancing left frontal lobe brain activity.
In PD and PDD, cholinergic deficits are profound and widespread (28). Although ChEIs
impact a diverse range of cognitive functions in PD, frontally-mediated and externally-
focused attention and executive functions appear to benefit the most (1, 2). In a previous
SPECT study, ChEI treatment in PDD was associated with increases in regional cerebral
blood flow in the bilateral anterior cingulate cortex, the bilateral superior frontal gyri, the
left precentral gyrus, the left superior frontal gyrus, and bilateral frontal white matter (29). In
the present study, increases in spontaneous brain activity in left frontal regions were
associated with improvements in controlled attention. Why ChEI treatment preferentially
enhances brain activity in the left hemisphere remains uncertain, but this lateralization result
could help explain the strong correlation with the CPT, which was completed using the right
hand in all individuals. The CPT requires successful interplay between controlled attention
and motor preparation of the dominant hand. Taken together, ChEI treatment in cognitively
impaired PD may help to restore brain activity in left frontal regions and support frontal
functions including controlled attention.
At baseline, we detected numerous regions of decreased spontaneous brain activity in the
patients compared to controls. The caudate and lateral frontal cortex findings are consistent
with known frontal-striatal dysfunction in PD (30). The prominent medial occipital
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reductions may reflect the severe acetylcholine activity reductions in this region (28).
Findings of decreased spontaneous brain activity in the precuneus, posterior cingulate, and
the angular gyrus might reflect the co-occurrence of Alzheimer’s pathology in some of the
sample. Interestingly, decreased spontaneous brain activity was not observed in the
brainstem or amygdala, some of the earliest areas affected by Lewy pathology (13). Our
results converge with previous findings of ALFF reductions in the bilateral supplementary
motor area, the left middle frontal gyrus, the right precentral gyrus, the inferior occipital
gyrus and the cerebellum (31), and of ALFF reductions in the left rolandic operculum(32) in
PD. The only previous report of fALFF in PD also found prefrontal decreases whilst ON but
not OFF dopaminergic medication (33).
The present study lacked a placebo-treated comparison sample, and it is possible that some
factor other than the effect of rivastigmine, such as disease progression, caused the
functional brain changes. Post-treatment fALFF results were much more similar to controls,
however, than were the pre-treatment results, and gains in left frontal regions were
paralleled by improved attention. These observations suggest that a positive “restoring”
treatment effect, rather than disease progression, is likely to account for the reported
findings. It is also important to note that PD patients respond variably to ChEIs(7), and not
all patients in this study evidenced improved attention. Those that responded in terms of
improved attention were more likely to show the increased frontal brain activity.
In summary, we used a new metric of brain activity measured during task-free fMRI to
evaluate the effects of rivastigmine in cognitively impaired PD. This metric appears to be
sensitive to the pathophysiological effects of PD, as the patients showed extensive
reductions in spontaneous brain activity compared to controls. Treatment was associated
with a restoration of spontaneous brain activity in the left precentral and inferior frontal gyri
and in the left supplementary motor area. Brain activity increase in the left precentral and
inferior frontal gyri was associated with improvements in controlled attention but not in
global cognitive function. ChEI treatment may improve attention and executive functions by
increasing the power of spontaneous brain activity in the left frontal lobe.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This study was supported by grants from Novartis Pharmaceuticals (Kramer, CENA713D US45T), the National
Institute on Aging (Possin, K23AG037566), and by the Larry L. Hillblom Foundation (Miller, 2007/2I). We are
grateful to our research participants for their generous time and efforts.
References
1. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic
denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006; 253(2):242–247.
[PubMed: 16133720]
2. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;
221(2):564–573. [PubMed: 20060022]
Possin et al. Page 8
Mov Disord. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
3. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s disease
and Alzheimer’s disease: similarities and differences. J Alzheimers Dis. 2007; 11(4):509–519.
[PubMed: 17656830]
4. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in
parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.
Arch Neurol. 2003; 60(12):1745–1748. [PubMed: 14676050]
5. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s
disease. N Engl J Med. 2004; 351(24):2509–2518. [PubMed: 15590953]
6. Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer’s Disease and Parkinson’s Disease
Dementia: An ADAS-Cog Factor Analysis. Am J Alzheimers Dis Other Demen.
7. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in
dementia associated with Parkinson disease. Neurology. 2005; 65(10):1654–1656. [PubMed:
16301500]
8. Zou QH, Zhu CZ, Yang Y, et al. An improved approach to detection of amplitude of low-frequency
fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J Neurosci Methods. 2008; 172(1):
137–141. [PubMed: 18501969]
9. Guo, C.; Gorno-Tempini, ML.; Gesierich, B., et al. Multimodal connectivity to the anterior temporal
hub: an integrated account of semantic memory. under review
10. Zuo XN, Di Martino A, Kelly C, et al. The oscillating brain: complex and reliable. Neuroimage.
2010; 49(2):1432–1445. [PubMed: 19782143]
11. Mennes M, Zuo XN, Kelly C, et al. Linking inter-individual differences in neural activation and
behavior to intrinsic brain dynamics. Neuroimage. 2012; 54(4):2950–2959. [PubMed: 20974260]
12. Hoptman MJ, Zuo XN, Butler PD, et al. Amplitude of low-frequency oscillations in schizophrenia:
a resting state fMRI study. Schizophr Res. 2010; 117(1):13–20. [PubMed: 19854028]
13. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of
Parkinson’s disease-related pathology. Cell Tissue Res. 2004; 318(1):121–134. [PubMed:
15338272]
14. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol. 1997;
48:649–684. [PubMed: 9046571]
15. Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection
on multiple timescales. Neuron. 2007; 56(1):141–154. [PubMed: 17920021]
16. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of
cognition. Neuropsychopharmacology. 2011; 36(1):52–73. [PubMed: 20668433]
17. McGaughy J, Kaiser T, Sarter M. Behavioral vigilance following infusions of 192 IgG-saporin into
the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive
fiber density. Behav Neurosci. 1996; 110(2):247–265. [PubMed: 8731052]
18. Bettcher BM, Wilheim R, Rigby T, et al. C-reactive protein is related to memory and medial
temporal brain volume in older adults. Brain Behav Immun. 26(1):103–108. [PubMed: 21843630]
19. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal
dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol. 2003; 16(4):211–218.
[PubMed: 14665820]
20. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia:
recommendations from the movement disorder society task force. Mov Disord. 2007; 22(16):
2314–2324. [PubMed: 18098298]
21. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in
Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011; 26(10):1814–1824. [PubMed:
21661055]
22. Van Dijk KR, Sabuncu MR, Buckner RL. The influence of head motion on intrinsic functional
connectivity MRI. Neuroimage. 2012; 59(1):431–438. [PubMed: 21810475]
23. Zang YF, He Y, Zhu CZ, et al. Altered baseline brain activity in children with ADHD revealed by
resting-state functional MRI. Brain Dev. 2007; 29(2):83–91. [PubMed: 16919409]
24. Wang Z, Yan C, Zhao C, et al. Spatial patterns of intrinsic brain activity in mild cognitive
impairment and Alzheimer’s disease: a resting-state functional MRI study. Hum Brain Mapp.
32(10):1720–1740. [PubMed: 21077137]
Possin et al. Page 9
Mov Disord. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
25. Flodin P, Gospic K, Petrovic P, Fransson P. Effects of L-dopa and oxazepam on resting-state
functional magnetic resonance imaging connectivity: a randomized, cross-sectional placebo study.
Brain Connect. 2012; 2(5):246–253. [PubMed: 22957904]
26. Poline JB, Worsley KJ, Evans AC, Friston KJ. Combining spatial extent and peak intensity to test
for activations in functional imaging. Neuroimage. 1997; 5(2):83–96. [PubMed: 9345540]
27. Kriegeskorte N, Simmons WK, Bellgowan PS, Baker CI. Circular analysis in systems
neuroscience: the dangers of double dipping. Nat Neurosci. 2009; 12(5):535–540. [PubMed:
19396166]
28. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy
body disease by PET. Neurology. 2009; 73(4):273–278. [PubMed: 19474411]
29. Ceravolo R, Volterrani D, Frosini D, et al. Brain perfusion effects of cholinesterase inhibitors in
Parkinson’s disease with dementia. J Neural Transm. 2006; 113(11):1787–1790. [PubMed:
16758132]
30. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and
striato-frontal dopamine release in Parkinson’s disease. Brain. 2008; 131(Pt 5):1294–1302.
[PubMed: 18362097]
31. Skidmore FM, Yang M, Baxter L, et al. Reliability analysis of the resting state can sensitively and
specifically identify the presence of Parkinson disease. Neuroimage. 2011
32. Long D, Wang J, Xuan M, et al. Automatic classification of early Parkinson’s disease with
multimodal MR imaging. PLoS One. 2012; 7(11):e47714. [PubMed: 23152757]
33. Kwak Y, Peltier SJ, Bohnen NI, Muller ML, Dayalu P, Seidler RD. L-DOPA changes spontaneous
low-frequency BOLD signal oscillations in Parkinson’s disease: a resting state fMRI study. Front
Syst Neurosci. 2012; 6:52. [PubMed: 22783172]
34. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose
equivalency reporting in Parkinson’s disease. Mov Disord. 25(15):2649–2653. [PubMed:
21069833]
Possin et al. Page 10
Mov Disord. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Patients with PD show distributed reductions compared to controls in brain activity as measured by fALFF at both baseline (red)
and post-treatment (blue); the overlap is shown in purple. Results are generated with a joint height-extent threshold (p<0.01
peak height and p<0.05 extent). PD showed no significant increases compared to controls at either timepoint. ACC = anterior
cingulate; MFG = middle frontal gyrus; IFG = inferior frontal gyrus; SMA = supplementary motor area; CN = caudate nucleus;
PcG = precentral gyrus; THAL = thalamus; PCUN = precuneus; PoG = postcentral gyrus; HC = hippocampus; CaC = calcarine
cortex; PD = Parkinson’s disease; NC = normal controls.
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Figure 2.
A. Regions where PD patients showed greater fALFF at post-treatment compared to baseline. B. Bar graphs depict mean
fALLF*100 with standard errors bars for each cluster by group. At baseline, the PD patients differed in mean fALLF in each
cluster from post-treatment and from the NCs; the PD patients post-treatment did not differ from controls. C. The increase in
local functional activity (mean falff*100) in the left precentral/inferior frontal gyri (PCG/IFG) cluster correlates significantly
with improvement on the Continuous Performance Test (CPT). No other correlations with cognitive change scores were
significant, including the correlation between this cluster and change on the Montreal Cognitive Assessment (MoCA) or the
correlations between improvement in the left supplementary motor (SMA) cluster and change on the CPT or MoCA. Negative
scores on the CPT Change indicate faster median reaction times (milliseconds) after treatment, and positive scores on the MoCA
Change indicate higher MoCA scores after treatment.
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